文献速递肺栓塞与肺血管病呼吸道感染间质性肺疾病

腹腔镜抗反流手术治疗特发性肺纤维化:WRAP-IPF 多中心随机对照 2 期试验

Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2018-08-09

手术安全可耐受。

要点

  • 对 IPF 合并异常酸反流患者,腹腔镜抗反流手术安全且耐受良好。
  • 术后最常见不良事件为吞咽困难(8/28,29%)和腹胀(4/28,14%)。

核心结论

  • 腹腔镜抗反流手术在 IPF 合并异常酸 GER 患者中安全且耐受良好,但本研究未显示其显著减少 48 周 FVC 下降,需更大样本的随机对照研究验证。

研究设计与样本

  • WRAP-IPF 为在美国 6 家学术中心开展的多中心、随机、对照 2 期试验,筛查 72 例后随机分配 58 例患者至手术组(n=29)或不手术组(n=29)。

主要发现

  • 急性加重、呼吸相关住院和死亡在手术组较少,但无统计学显著性;手术组死亡 1 例,不手术组死亡 4 例。
  • 术后最常见不良事件为吞咽困难(8/28,29%)和腹胀(4/28,14%)。

关键数值与推荐

  • 主要终点为随机化至第 48 周 FVC 变化,采用重复测量混合效应模型在意向性治疗人群中分析。

临床怎么用

  • 对 IPF 合并异常酸 GER 且 FVC 保留的患者,可考虑腹腔镜抗反流手术,但应告知现有证据未证实其显著延缓 FVC 下降。
  • 术前需评估吞咽功能与腹部症状风险,术后关注吞咽困难和腹胀。
  • 是否手术应个体化决策,并与抗纤维化治疗综合管理。

局限性

  • 样本量小(58 例),主要终点组间差异无统计学意义,研究把握度不足。
  • 作者指出需要更大规模、把握度充分的随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abnormal acid gastro-oesophageal reflux (GER) is hypothesised to play a role in progression of idiopathic pulmonary fibrosis (IPF). We aimed to determine whether treatment of abnormal acid GER with laparoscopic anti-reflux surgery reduces the rate of disease progression. METHODS: The WRAP-IPF trial was a randomised controlled trial of laparoscopic anti-reflux surgery in patients with IPF and abnormal acid GER recruited from six academic centres in the USA. We enrolled patients with IPF, abnormal acid GER (DeMeester score of ≥14·7; measured by 24-h pH monitoring) and preserved forced vital capacity (FVC). We excluded patients with a FVC below 50% predicted, a FEV1/FVC ratio of less than 0·65, a history of acute respiratory illness in the past 12 weeks, a body-mass index greater than 35, and known severe pulmonary hypertension. Concomitant therapy with nintedanib and pirfenidone was allowed. The primary endpoint was change in FVC from randomisation to week 48, in the intention-to-treat population with mixed-effects models for repeated measures. This trial is registered with ClinicalTrials.gov, number NCT01982968. FINDINGS: Between June 1, 2014, and Sept 30, 2016, we screened 72 patients and randomly assigned 58 patients to receive surgery (n=29) or no surgery (n=29). 27 patients in the surgery group and 20 patients in the no surgery group had an FVC measurement at 48 weeks (p=0·041). Intention-to-treat analysis adjusted for baseline anti-fibrotic use demonstrated the adjusted rate of change in FVC over 48 weeks was -0·05 L (95% CI -0·15 to 0·05) in the surgery group and -0·13 L (-0·23 to -0·02) in the non-surgery group (p=0·28). Acute exacerbation, respiratory-related hospitalisation, and death was less common in the surgery group without statistical significance. Dysphagia (eight [29%] of 28) and abdominal distention (four [14%] of 28) were the most common adverse events after surgery. There was one death in the surgery group and four deaths in the non-surgery group. INTERPRETATION: Laparoscopic anti-reflux surgery in patients with IPF and abnormal acid GER is safe and well tolerated. A larger, well powered, randomised controlled study of anti-reflux surgery is needed in this population. FUNDING: US National Institutes of Health National Heart, Lung and Blood Institute.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018. PMID: 30100404. doi:10.1016/S2213-2600(18)30301-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。